← Leaderboards

Malcolm K Brenner

Baylor College Of Medicine

Google Scholar ↗PubMed ↗ORCID ↗

$13,204,649

Attributed

$14,211,964

Total exposure

51

Grants

31

Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $5M · FY2005–25

$10M$7.5M$5M$2.5M$0

'05

'06

'07

'08

'09

'10

'11

'12

'13

'14

'15

'16

'17

'18

'19

'20

'21

'22

'23

'24

'25

Funding mix

By agency

NIH$56,131,954 · 54

By mechanism

P50$35,018,931 · 8

U54$10,163,652 · 3

U42$4,775,774 · 4

P01$1,655,789 · 2

T32$1,544,267 · 1

R21$1,388,932 · 3

Top collaborators

Most similar at Baylor College Of Medicine

Same institution · by research overlap

Helen E Heslop$25,308,937
Cliona M Rooney$13,445,584
Ravi K Ghanta$3,520,284
Terzah M Horton$4,270,013
Richard A Cox$1,950,589

Others in their field

Top investigators on “Clinical Research”

David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
Sonia M Thomas · Research Triangle Institute$700,865,642
Jeffrey P Krischer · University Of South Florida$611,867,176
Barton F Haynes · Duke University$538,862,577

Research focus

Clinical ResearchResearch PersonnelEnsureCellsFundingLymphomaTumorSuccessT-LymphocyteProgramsSourceSafetyCollegeHospitalsMedicineMethodist ChurchResourcesClinical TrialsFutureTranslational ResearchMalignant NeoplasmsInstitutionNeoplastic CellNovel Strategies

Grant awards (119)

SPORE in Lymphoma$3,109,934

P50 · FY2025 · CA

Project 2: CAR-T cell therapy for T cell lymphoma$1,269,725

P50 · FY2025 · CA · contact PI

Training In Cell and Gene Therapy$518,127

T32 · FY2025 · HL

Developmental Research Program 1$127,937

P50 · FY2025 · CA · contact PI

SPORE in Lymphoma$2,075,728

P50 · FY2024 · CA

Training In Cell and Gene Therapy$503,875

T32 · FY2024 · HL

Project 2: CAR-T cell therapy for T cell lymphoma$332,425

P50 · FY2024 · CA · contact PI

Developmental Research Program 1$126,330

P50 · FY2024 · CA · contact PI

SPORE in Lymphoma$2,048,062

P50 · FY2023 · CA

Training In Cell and Gene Therapy$522,265

T32 · FY2023 · HL

Project 2: CAR-T cell therapy for T cell lymphoma$361,547

P50 · FY2023 · CA · contact PI

Developmental Research Program 1$156,002

P50 · FY2023 · CA · contact PI

SPORE in Lymphoma$2,062,012

P50 · FY2022 · CA

Project 2: CAR-T cell therapy for T cell lymphoma$328,089

P50 · FY2022 · CA · contact PI

Developmental Research Program 1$124,686

P50 · FY2022 · CA · contact PI

SPORE in Lymphoma$2,133,312

P50 · FY2021 · CA

CAR T cell therapy for T cell lymphoma$252,360

P50 · FY2021 · CA · contact PI

Developmental Research Program$104,315

P50 · FY2021 · CA · contact PI

SPORE in Lymphoma$2,179,484

P50 · FY2020 · CA

CAR T cell therapy for T cell lymphoma$299,192

P50 · FY2020 · CA · contact PI

Developmental Research Program$100,679

P50 · FY2020 · CA · contact PI

SPORE in Lymphoma$2,636,949

P50 · FY2019 · CA

CAR T cell therapy for T cell lymphoma$311,574

P50 · FY2019 · CA · contact PI

Developmental Research Program$128,787

P50 · FY2019 · CA · contact PI

SPORE in Lymphoma$2,297,796

P50 · FY2018 · CA

CAR T cell therapy for T cell lymphoma$271,354

P50 · FY2018 · CA · contact PI

Developmental Research Program$112,168

P50 · FY2018 · CA · contact PI

SPORE in Lymphoma$3,097,657

P50 · FY2017 · CA

CAR T cell therapy for T cell lymphoma$260,351

P50 · FY2017 · CA · contact PI

Developmental Research Program$100,042

P50 · FY2017 · CA · contact PI

SPORE in Lymphoma$2,344,258

P50 · FY2016 · CA

SPORE in Lymphoma$300,703

P50 · FY2016 · CA

DEVELOPMENTAL RESEARCH PROGRAM$155,811

P50 · FY2016 · CA · contact PI

SPORE in Lymphoma$2,184,999

P50 · FY2015 · CA

DEVELOPMENTAL RESEARCH PROGRAM$157,467

P50 · FY2015 · CA · contact PI

SPORE in Lymphoma$2,162,000

P50 · FY2014 · CA

DEVELOPMENTAL RESEARCH PROGRAM$155,811

P50 · FY2014 · CA · contact PI

Program leaders---cell and gene therapy$13,118

P30 · FY2014 · CA · contact PI

Chimeric T Cells Targeting Neuroblastoma$296,275

P01 · FY2013 · CA · contact PI

DEVELOPMENTAL RESEARCH PROGRAM$152,167

P50 · FY2013 · CA · contact PI

Program leaders---cell and gene therapy$57,350

P30 · FY2013 · CA · contact PI

CHIMERIC T CELLS TARGETING NEUROBLASTOMA$267,201

P01 · FY2012 · CA · contact PI

DEVELOPMENTAL RESEARCH PROGRAM$165,756

P50 · FY2012 · CA · contact PI

Program leaders---cell and gene therapy$15,004

P30 · FY2012 · CA · contact PI

CHIMERIC T CELLS TARGETING NEUROBLASTOMA$269,122

P01 · FY2011 · CA · contact PI

Research Development$152,964

P50 · FY2011 · CA · contact PI

CASPALLO: A PHASE I STUDY EVALUATING THE USE OF ALLODEPLETED T CELLS TRANSDUCED$17,414

M01 · FY2011 · RR · contact PI

Program leaders---cell and gene therapy$15,839

P30 · FY2011 · CA · contact PI

CLINICAL TRIAL: CRETI-NH -- PHASE I STUDY OF CD19 CHIMERIC RECEPTOR EXPRESSING$15,435

M01 · FY2011 · RR · contact PI

CLINICAL TRIAL: PROLONGED IMMUNIZATION WITH AUTOLOGOUS CD-40 LIGAND AND IL-1-EX$3,166

M01 · FY2011 · RR · contact PI

CHIMERIC T CELLS TARGETING NEUROBLASTOMA$279,346

P01 · FY2010 · CA · contact PI

Research Development$184,258

P50 · FY2010 · CA · contact PI

Program leaders---cell and gene therapy$17,826

P30 · FY2010 · CA · contact PI

CLINICAL TRIAL: PROLONGED IMMUNIZATION WITH AUTOLOGOUS CD-40 LIGAND AND IL-1-EXP$14,498

M01 · FY2010 · RR · contact PI

CLINICAL TRIAL: CRETI-NH -- PHASE I STUDY OF CD19 CHIMERIC RECEPTOR EXPRESSING T$4,959

M01 · FY2010 · RR · contact PI

CASPALLO: A PHASE I STUDY EVALUATING THE USE OF ALLODEPLETED T CELLS TRANSDUCED$4,578

M01 · FY2010 · RR · contact PI

Improving the safety and efficacy of cell therapies$2,115,190

U54 · FY2009 · HL · contact PI

CHIMERIC T CELLS TARGETING NEUROBLASTOMA$275,789

P01 · FY2009 · CA · contact PI

Research Development$185,587

P50 · FY2009 · CA · contact PI

CLINICAL TRIAL: PROLONGED IMMUNIZATION WITH AUTOLOGOUS CD-40 LIGAND AND IL-1-EXP$20,737

M01 · FY2009 · RR · contact PI

CLINICAL TRIAL: TREATMENT OF CHRONIC LYMPHOCYTIC B-LEUKEMIA (B-CLL) WITH HUMAN I$593

M01 · FY2009 · RR · contact PI

CLINICAL TRIAL: CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) TREATMENT WITH MOD AUTOLOGOU$296

M01 · FY2009 · RR · contact PI

PROCUREMENT OF TISSUE FOR AUTOLOGOUS TUMOR VACCINE PREPARATION$296

M01 · FY2009 · RR · contact PI

Improving the safety and efficacy of cell therapies$2,018,471

U54 · FY2008 · HL · contact PI

CHIMERIC T CELLS TARGETING NEUROBLASTOMA$268,056

P01 · FY2008 · CA · contact PI

Research Development$158,635

P50 · FY2008 · CA · contact PI

CLINICAL TRIAL: PROLONGED IMMUNIZATION WITH AUTOLOGOUS CD-40 LIGAND AND IL-1-EXP$11,824

M01 · FY2008 · RR · contact PI

CLINICAL TRIAL: TREATMENT OF CHRONIC LYMPHOCYTIC B-LEUKEMIA (B-CLL) WITH HUMAN I$8,477

M01 · FY2008 · RR · contact PI

CLINICAL TRIAL: RFT5-DGA TO DEPLETE ALLOREACTIVE CELLS PRIOR TO HAPLOIDENTICAL$223

M01 · FY2008 · RR · contact PI

Improving the safety and efficacy of cell therapies$2,005,762

U54 · FY2007 · HL · contact PI

Research Development$150,018

P50 · FY2007 · CA · contact PI

TREATMENT OF CHRONIC LYMPHOCYTIC B-LEUKEMIA (B-CLL) WITH HUMAN IL-2 AND CD40$3,222

M01 · FY2007 · RR · contact PI

RFT5-DGA TO DEPLETE ALLOREACTIVE CELLS PRIOR TO HAPLOIDENTICAL STEM CELL TRANSP$2,929

M01 · FY2007 · RR · contact PI

CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) TREATMENT WITH MOD AUTOLOGOUS TUMOR CELLS$293

M01 · FY2007 · RR · contact PI

Improving the safety and efficacy of cell therapies$2,011,769

U54 · FY2006 · HL · contact PI

ADENOVIRAL VECTOR PRODUCTION AT BAYLOR$514,305

U42 · FY2006 · RR · contact PI

ESTABLISHMENT OF ADENOVIRAL VECTOR PRODUCTION LAB AT BAYLOR$514,305

U42 · FY2006 · RR · contact PI

TREATMENT OF CHRONIC LYMPHOCYTIC B-LEUKEMIA (B-CLL) WITH HUMAN IL-2 AND CD40$26,364

M01 · FY2006 · RR · contact PI

RFT5-DGA TO DEPLETE ALLOREACTIVE CELLS PRIOR TO HAPLOIDENTICAL STEM CELL TRANSP$12,717

M01 · FY2006 · RR · contact PI

CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) TREATMENT WITH MOD AUTOLOGOUS TUMOR CELLS$9,926

M01 · FY2006 · RR · contact PI

RFT5-DGA TO DEPLETE ALLOREACTIVE CELLS WITH SUBMYELOABLATIVE CONDITIONING$310

M01 · FY2006 · RR · contact PI

Improving the safety and efficacy of cell therapies$2,012,460

U54 · FY2005 · HL

ADENOVIRAL VECTOR PRODUCTION AT BAYLOR$526,682

U42 · FY2005 · RR

ESTABLISHMENT OF ADENOVIRAL VECTOR PRODUCTION LAB AT BAYLOR$526,682

U42 · FY2005 · RR

Combined CTL and CD45 antibody for nasopharyngeal carci*$308,013

R21 · FY2005 · CA

CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) TREATMENT WITH MOD AUTOLOGOUS TUMOR CELLS$43,952

M01 · FY2005 · RR

TREATMENT OF CHRONIC LYMPHOCYTIC B-LEUKEMIA (B-CLL) WITH HUMAN IL-2 AND CD40$9,603

M01 · FY2005 · RR

RFT5-DGA TO DEPLETE ALLOREACTIVE CELLS PRIOR TO HAPLOIDENTICAL STEM CELL TRANSP$5,227

M01 · FY2005 · RR

PHASE I STUDY OF CHEMOKINE AND CYTOKINE GENE MODIFIED ALLOGENEIC NEUROBLASTOMA$3,324

M01 · FY2005 · RR

RFT5-DGA TO DEPLETE ALLOREACTIVE CELLS WITH SUBMYELOABLATIVE CONDITIONING$2,585

M01 · FY2005 · RR

LEUKEMIA THERAPY USING A CD40 LIGAND AND IL-2 GENE MODIFIED TUMOR VACCINE$1,847

M01 · FY2005 · RR

Validation of Suicide Strategies for Cellular Therapy$0

U54 · FY2005 · HL

Multipathogen-Specific CTL for the Immunocompromised$0

U54 · FY2005 · HL

ADENOVIRAL VECTOR PRODUCTION AT BAYLOR$611,343

U42 · FY2004 · RR

ESTABLISHMENT OF ADENOVIRAL VECTOR PRODUCTION LAB AT BAYLOR$611,343

U42 · FY2004 · RR

Combined CTL /CD45 antibody for nasopharyngeal carcinoma$308,013

R21 · FY2004 · CA

Leukemia Therapy Using a CD40 Ligand /IL-2 gene Modified$17,037

M01 · FY2004 · RR

Chronic Lymphocytic Leukemia (CLL) Treatment with Mod. Autologous Tumor Cells$8,945

M01 · FY2004 · RR

RFT5-DGA to Deplete Alloreactive Cells Prior to Haploidentical Stem Cell Transp$3,834

M01 · FY2004 · RR

Phase I Study of Chemokine /Cytokine Gene Modified Allog$2,981

M01 · FY2004 · RR

ADENOVIRAL VECTOR PRODUCTION AT BAYLOR$496,450

U42 · FY2003 · RR

ADENOVIRAL VECTOR PRODUCTION AT BAYLOR$491,441

U42 · FY2002 · RR

Haploidentical Allogeneic Transplantation$289,148

R21 · FY2002 · CA

THERAPEUTIC EFFECTS OF CD40L IN ACUTE LYMPHOBLASTIC LEUK$231,196

R01 · FY2002 · CA

5th Annual Meeting, American Society of Gene Therapy$24,000

R13 · FY2002 · DK

Chimeric EBV Specific T Cells with Anti Tumor Activity$0

P01 · FY2002 · CA

ADENOVIRAL VECTOR PRODUCTION$483,223

U42 · FY2001 · RR

Haploidentical Allogeneic Transplantation$321,692

R21 · FY2001 · CA

ACTIVITY OF LYMPHOTACTIN IN CHILDHOOD MALIGNANCY$256,385

R01 · FY2001 · CA

THERAPEUTIC EFFECTS OF CD40L IN ACUTE LYMPHOBLASTIC LEUK$225,587

R01 · FY2001 · CA

CHEMOKINE/CYTOKINE GENE THERAPY OF NEUROBLASTOMA--RETROVIRAL VECTOR$0

M01 · FY2001 · RR

ANTI CD45 MAB IN LEUKEMIA PRIOR TO STEM CELL TRANSPLANTS$0

M01 · FY2001 · RR

CHEMOKINE/CYTOKINE GENE THERAPY OF NEUROBLASTOMA--ADENOVIRAL VECTOR$0

M01 · FY2001 · RR

ACTIVITY OF LYMPHOTACTIN IN CHILDHOOD MALIGNANCY$250,573

R01 · FY2000 · CA

THERAPEUTIC EFFECTS OF CD40L IN ACUTE LYMPHOBLASTIC LEUK$220,139

R01 · FY2000 · CA

CD45 ANTIBODY EFFECT ON NORMAL AND MALIGNANT HEMOPOIESIS$162,066

R21 · FY2000 · CA

CHEMOKINE/CYTOKINE GENE THERAPY OF NEUROBLASTOMA--RETROVIRAL VECTOR$0

M01 · FY2000 · RR

ANTI CD45 MAB IN LEUKEMIA PRIOR TO STEM CELL TRANSPLANTS$0

M01 · FY2000 · RR

CHEMOKINE/CYTOKINE GENE THERAPY OF NEUROBLASTOMA--ADENOVIRAL VECTOR$0

M01 · FY2000 · RR